Glutathione (GSH) is an endogenous tripeptide thiol, gamma-L-glutamyl-L-cysteinylglycine, widely described in the biochemical literature as the most abundant low-molecular-weight non-protein thiol in mammalian cells. It functions as a redox buffer, a direct scavenger of reactive oxygen and nitrogen species, an obligatory cofactor for glutathione peroxidases and glutathione S-transferases, and a substrate for reversible protein S-glutathionylation. This monograph summarizes the published scientific literature on its chemistry, biosynthesis, mechanisms, and research applications. It is presented for laboratory and research use only.

Background & Discovery

Glutathione is an endogenous tripeptide thiol widely characterized in the biochemical literature as the most abundant low-molecular-weight non-protein thiol in mammalian cells, where it is typically present at millimolar (roughly 1-10 mM) intracellular concentrations. Historical accounts trace its discovery to 1888, when de Rey-Pailhade described a sulfur-containing reducing substance in yeast and animal tissues that he named "philothion." In the 1920s Frederick Gowland Hopkins isolated and named the compound glutathione and, with later contributions from Edward Kendall and others, established it as a tripeptide of glutamate, cysteine, and glycine; the structure was confirmed by the chemical synthesis of Harington and Mead in 1935. The subsequent work of Alton Meister and colleagues elaborated the enzymology of its biosynthesis and the gamma-glutamyl cycle, providing the framework that still organizes the field.

Glutathione is studied because it sits at the center of cellular redox homeostasis. Its reactive cysteinyl thiol allows it to serve simultaneously as a redox buffer, a direct scavenger of reactive oxygen and nitrogen species, an obligatory cofactor for the glutathione peroxidase and glutathione S-transferase enzyme families, and a substrate for protein S-glutathionylation, a reversible post-translational modification implicated in redox signaling. The intracellular ratio of reduced glutathione (GSH) to its oxidized disulfide form (GSSG) is one of the most widely used indices of cellular redox state.

In the research-chemical context, glutathione is categorized as an endogenous tripeptide thiol antioxidant and enzyme cofactor. Published literature examines it both as an intrinsic metabolite whose depletion or dysregulation is associated with the etiology and progression of numerous disease states, and as an exogenously supplied compound in pharmacology and supplementation studies. It is offered for laboratory and research use only, and the material below summarizes what peer-reviewed studies report rather than making any therapeutic or human-use claim.

Chemical Identity

Structure & Physicochemical Properties

Structurally, glutathione is distinguished from ordinary tripeptides by an unusual gamma-glutamyl isopeptide bond: the glutamate residue is linked to cysteine through its gamma-carboxyl group rather than the alpha-carboxyl. This linkage renders the molecule resistant to cleavage by common intracellular peptidases and aminopeptidases; essentially only the cell-surface enzyme gamma-glutamyl transpeptidase can hydrolyze it, a feature central to interorgan glutathione turnover in the gamma-glutamyl cycle. The C-terminal cysteine bears the free sulfhydryl group that is the chemically reactive center responsible for antioxidant and nucleophilic conjugation chemistry, while the two carboxylates and the alpha-amino group make the molecule zwitterionic with an isoelectric point near 5.9.

Physicochemically, glutathione is a white crystalline solid, highly soluble in water and poorly soluble in ethanol and most nonpolar organic solvents. Reference databases list a melting point in the region of 190-195 degrees C with decomposition. The reduced (GSH) form is thermodynamically prone to autoxidation to the disulfide (GSSG), a reaction that is accelerated at alkaline pH, at elevated temperature, upon exposure to air, and by trace transition-metal ions such as copper and iron that catalyze thiol oxidation. Because of this, solid glutathione and its solutions are typically handled under conditions that limit oxidation, and analytical work distinguishes carefully between the reduced and oxidized species.

Mechanism of Action — as described in the literature

Glutathione is synthesized de novo in the cytosol of virtually all cells by two sequential ATP-dependent ligation reactions. In the first and rate-limiting step, glutamate-cysteine ligase (GCL, also called gamma-glutamylcysteine synthetase) joins the gamma-carboxyl of glutamate to the amino group of cysteine to form the dipeptide gamma-glutamylcysteine. In the second step, glutathione synthetase adds glycine to yield the mature tripeptide. As reviewed by Lu and by Meister and Anderson, GCL activity is governed by the availability of cysteine (usually the limiting precursor), by non-allosteric feedback inhibition from glutathione itself, and by transcriptional induction of its catalytic and modifier subunits under oxidative and electrophilic stress, providing multi-level control over cellular glutathione content.

The best-characterized function of glutathione is its participation in the GSH/GSSG redox cycle. Glutathione peroxidases (a family of largely selenocysteine-dependent enzymes) use two molecules of GSH to reduce hydrogen peroxide and organic and lipid hydroperoxides to water and the corresponding alcohols, generating one molecule of the disulfide GSSG. The disulfide is then reduced back to GSH by NADPH-dependent glutathione reductase, so that the reduced pool is continuously regenerated at the expense of NADPH supplied largely by the pentose phosphate pathway. This cycle keeps the intracellular GSH:GSSG ratio high (often greater than 100:1 in healthy cytosol) and constitutes a major peroxide-detoxifying and redox-buffering system that works alongside the thioredoxin and peroxiredoxin systems.

Beyond enzymatic peroxide reduction, glutathione acts through direct thiol chemistry. Its sulfhydryl group scavenges reactive oxygen and nitrogen species, quenches free radicals, and reacts with electrophiles. It also participates in reversible protein S-glutathionylation, in which mixed disulfides form between GSH and protein cysteine residues; this modification protects protein thiols from irreversible overoxidation and serves as a redox-signaling switch that modulates the activity of many enzymes, transcription factors, and structural proteins.

A distinct and pharmacologically important role is in phase II biotransformation. Glutathione S-transferases catalyze the nucleophilic conjugation of the GSH thiol to a broad range of electrophilic and xenobiotic substrates, forming glutathione conjugates that are subsequently processed to mercapturic acids and excreted. This detoxification pathway is exemplified by the conjugation of the reactive acetaminophen metabolite NAPQI, and glutathione depletion is a recognized determinant of susceptibility to electrophile-mediated toxicity, as summarized in the reviews by Forman, Zhang and Rinna and by Wu and colleagues.

Finally, glutathione is the essential reducing substrate for glutathione peroxidase 4 (GPX4), the enzyme that reduces phospholipid hydroperoxides within membranes. Work by Yang and colleagues established that depletion of glutathione inactivates GPX4 and that loss of GPX4 activity triggers ferroptosis, an iron-dependent, non-apoptotic form of regulated cell death driven by unchecked lipid peroxidation. This mechanism has made the glutathione-GPX4 axis a focal point in cancer, neurodegeneration, and cell-death research, and it connects glutathione biosynthesis and transport (the gamma-glutamyl cycle) directly to cellular survival decisions.

Key Published Findings

• Oral supplementation and body stores. In a 6-month randomized, double-blind, placebo-controlled trial in 54 healthy non-smoking adults, researchers reported that daily oral glutathione (250 or 1000 mg/day) raised glutathione levels relative to baseline, with increases of roughly 30-35% in erythrocytes, plasma and lymphocytes and about 260% in buccal-mucosa cells in the high-dose group, providing evidence that oral GSH can increase body-compartment stores in humans.[4]
• GPX4, glutathione depletion and ferroptosis. Using targeted metabolomic and chemoproteomic profiling across cancer cell lines, investigators demonstrated that glutathione depletion inactivates glutathione peroxidases and that GPX4 is the direct target whose loss drives ferroptotic cell death, establishing the glutathione-GPX4 axis as an essential regulator of this iron-dependent, lipid-peroxidation-driven death pathway.[2]
• Precursor availability and GSH synthesis in metabolic disease. In patients with uncontrolled type 2 diabetes, researchers observed lower erythrocyte cysteine and glycine, reduced glutathione concentrations, and diminished fractional and absolute GSH synthesis rates versus controls; dietary supplementation with the precursors cysteine and glycine restored GSH synthesis and concentrations and lowered markers of oxidative stress.[6]
• Comparative renal oxidative-stress model. In a clinical study of patients undergoing coronary angiography, intravenous glutathione was reported to prevent contrast-associated renal oxidative stress more effectively than oral N-acetylcysteine, as assessed by urinary oxidative-stress and renal markers.[7]
• Neurodegeneration pilot. In a small open pilot in nine patients with early, untreated Parkinson’s disease, intravenously administered glutathione was associated with an approximately 42% decline in disability that persisted for 2-4 months after the infusions were stopped; the authors framed the result as preliminary and warranting controlled study.[10]
• Biosynthesis and regulation. Authoritative reviews characterize glutathione biosynthesis as a two-step ATP-dependent process in which glutamate-cysteine ligase is rate-limiting and subject to feedback inhibition by GSH and to cysteine-availability constraints, framing GSH homeostasis as tightly regulated at the level of synthesis, utilization, and transport.[5]

Research Applications

• Investigated as the central redox couple (GSH/GSSG) in in-vitro and rodent models of oxidative stress and redox homeostasis
• Examined in phase II detoxification and xenobiotic-conjugation research, including electrophile trapping such as the acetaminophen metabolite NAPQI
• Studied as the essential reducing substrate in the GPX4-ferroptosis pathway in cancer cell lines and cell-death research
• Investigated in rodent and clinical models of neurodegeneration, including early Parkinson’s disease
• Examined in metabolic-disease and aging research, including glutathione synthesis in type 2 diabetes and older adults
• Studied in hepatology and drug-induced liver injury models where glutathione depletion modulates toxicity susceptibility
• Used as a redox biomarker, with GSH:GSSG ratio measured to index cellular and systemic oxidative status
• Investigated in immune-cell (lymphocyte) function and inflammation research
• Examined in dermatological and melanogenesis research relating thiols to tyrosinase activity and pigment biology

Related & Comparator Compounds

The literature situates glutathione within a family of thiol antioxidants and precursors that are frequently compared. N-acetylcysteine (NAC) is studied as a membrane-permeable cysteine precursor that raises intracellular cysteine to drive GSH synthesis, and it is the established antidote in acetaminophen toxicity; gamma-glutamylcysteine is the immediate biosynthetic intermediate downstream of the rate-limiting GCL step. The oxidized disulfide GSSG is the redox partner regenerated to GSH by glutathione reductase, and cell-permeable derivatives such as glutathione monoethyl ester and S-acetyl-glutathione are examined as forms designed to improve delivery relative to the polar parent tripeptide. Combination approaches such as GlyNAC (glycine plus NAC) are studied to supply both limiting precursors simultaneously. Glutathione also functions in concert with, and is often compared against, other antioxidant systems including the selenium-dependent glutathione peroxidases, the thioredoxin/peroxiredoxin system, alpha-lipoic acid, and ascorbate, with the literature distinguishing glutathione by its high intracellular abundance, its dual role as both direct scavenger and enzyme cofactor, and its unique gamma-glutamyl linkage and peptidase resistance.

Handling, Reconstitution & Storage

In research settings glutathione is commonly supplied as a lyophilized or crystalline powder and is typically stored desiccated at -20 degrees C, protected from light, air, and moisture, because the free thiol is prone to autoxidation to GSSG. For experimental use it is readily reconstituted in water or aqueous buffer near neutral to slightly acidic pH; solutions are often prepared fresh immediately before use, kept cold, and sometimes degassed or handled under inert atmosphere to limit oxidation, with avoidance of trace transition-metal contamination (or inclusion of a chelator such as EDTA) since metals catalyze thiol oxidation. Working stocks are frequently aliquoted to minimize repeated freeze-thaw cycles. These practices are described in the context of laboratory handling and stability only and are not human-use directions.

Analytical & Quality Considerations

Analytical characterization of glutathione centers on distinguishing and quantifying the reduced (GSH) and oxidized (GSSG) species and confirming identity and purity. Common approaches include reversed-phase HPLC with UV or electrochemical detection, thiol-specific spectrophotometric assays using Ellman’s reagent (DTNB), fluorometric derivatization with reagents such as monobromobimane or o-phthalaldehyde, and LC-MS/MS for sensitive and specific quantitation; enzymatic recycling assays are widely used for total glutathione and GSH:GSSG ratio determination. Identity is corroborated by high-resolution mass spectrometry (monoisotopic mass 307.0838) and NMR, while purity is assessed by HPLC area percent. Because the thiol oxidizes readily, a key quality concern is GSSG and other oxidation-product contamination, alongside residual moisture, counterion content, and elemental/heavy-metal impurities; for these reasons an independent third-party certificate of analysis (COA) reporting HPLC purity, confirmed identity, and GSH/GSSG content is important for verifying that research material matches its stated specification.

Frequently Asked Research Questions

Q. What is glutathione?
A. Glutathione is an endogenous tripeptide, gamma-L-glutamyl-L-cysteinylglycine (CAS 70-18-8; C10H17N3O6S; about 307.32 g/mol), that published literature characterizes as the most abundant intracellular non-protein thiol and a central antioxidant, redox buffer, and enzyme cofactor.

Q. What is the difference between GSH and GSSG?
A. GSH is the reduced form bearing a free cysteine thiol, while GSSG is the oxidized disulfide formed when two GSH molecules are joined. Glutathione peroxidases oxidize GSH to GSSG while reducing peroxides, and NADPH-dependent glutathione reductase regenerates GSH; the GSH:GSSG ratio is used as an index of cellular redox state.

Q. Why is the gamma-glutamyl bond significant?
A. The glutamate residue is linked through its gamma-carboxyl rather than its alpha-carboxyl, which makes the tripeptide resistant to most intracellular peptidases. Cleavage is essentially restricted to gamma-glutamyl transpeptidase, a feature that underlies the gamma-glutamyl cycle and interorgan glutathione turnover.

Q. Does published research indicate oral glutathione is bioavailable?
A. A 6-month randomized, placebo-controlled trial by Richie and colleagues reported that daily oral glutathione increased glutathione levels in blood compartments and buccal cells relative to baseline, providing evidence that oral GSH can raise body stores; this is reported here as a scientific finding, not as a health recommendation.

Q. How is glutathione connected to ferroptosis?
A. Glutathione is the reducing substrate for GPX4, the enzyme that detoxifies phospholipid hydroperoxides. Research by Yang and colleagues showed that glutathione depletion inactivates GPX4 and that loss of GPX4 activity triggers ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation.

Q. How is glutathione handled and analyzed in the laboratory?
A. It is typically stored as a desiccated powder at -20 degrees C protected from air and moisture because the thiol autoxidizes, and it is quantified by HPLC, DTNB or fluorometric thiol assays, enzymatic recycling assays, and LC-MS/MS, with identity confirmed by MS/NMR. This information is for research and laboratory use only.

Peer-Reviewed References

1. Meister A, Anderson ME. Glutathione. Annual Review of Biochemistry. 1983. PubMed →
2. Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014. PubMed →
3. Forman HJ, Zhang H, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Molecular Aspects of Medicine. 2009. PubMed →
4. Richie JP Jr, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, Schell TD, Muscat JE. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition. 2015. PubMed →
5. Lu SC. Glutathione synthesis. Biochimica et Biophysica Acta. 2013. PubMed →
6. Sekhar RV, McKay SV, Patel SG, Guthikonda AP, Reddy VT, Balasubramanyam A, Jahoor F. Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine. Diabetes Care. 2011. PubMed →
7. Saitoh T, Satoh H, Nobuhara M, Machii M, Tanaka T, Ohtani H, et al. Intravenous glutathione prevents renal oxidative stress after coronary angiography more effectively than oral N-acetylcysteine. Heart and Vessels. 2011. PubMed →
8. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. The Journal of Nutrition. 2004. PubMed →
9. Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL. Glutathione dysregulation and the etiology and progression of human diseases. Biological Chemistry. 2009. PubMed →
10. Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM, Rosati G. Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 1996. PubMed →

For laboratory and research use only. Not for human or veterinary use, diagnosis, or treatment. This overview summarizes published scientific literature for informational and educational purposes and is not medical advice; no claims are made regarding safety or efficacy in humans.

← Back to the Research Library · Browse our catalog → · COA & Testing